Karyopharm Therapeutics Inc.
KPTI Nasdaq· Pharmaceutical Preparations
Last close · Oct 23, 2026
$0.52
KIRA · Stoqly’s AI analyst, in plain words
- Karyopharm Therapeutics Inc. had $146M of revenue in fiscal 2025, up 0.6% on the year before. Over five years, revenue changed +6.2% a year on average.
- Its operating margin was −62.1%, up 20.1 pts: of every 100 in sales, about −62 is left after running the business.
- Karyopharm Therapeutics Inc. lost $196M in fiscal 2025.
- Free cash flow was −$75.4M in fiscal 2025, −51.6% of revenue.
Market cap
$0.0M
P/E
—
Revenue
$146M
Net income
−$196M
Free cash flow
−$75.4M
Operating margin
−62.1%
Karyopharm Therapeutics Inc. in 30 seconds · fiscal 2025
Are sales growing?
+0.6%
Only a little. Sales grew 0.6% last year.
Does it make a profit?
−134.2%
No. It lost money last year.
Does profit turn into cash?
−51.6%
No. It spent more cash than it brought in.
How healthy are the accounts?
2 / 7
Weak. It passes 2 of 7 health tests.
How is the share priced?
—
No P/E: it made no profit over the last four quarters.
What Karyopharm Therapeutics Inc. does
No business description yet.
- Fiscal year ends
- December 31, 2025
- Latest annual report
- 10-K · Feb 13, 2026
- Legal name
- Karyopharm Therapeutics Inc.
- CIK
- 0001503802
Karyopharm Therapeutics Inc. · KPTI
Results and finances
The last 5 fiscal years. Amounts in USD.
| Fiscal year | FY21 | FY22 | FY23 | FY24 | FY25 |
|---|---|---|---|---|---|
| Sales and profit | |||||
| Revenue | $210M | $157M | $146M | $145M | $146M |
| Revenue growth | 94.1% | −25.1% | −7.0% | −0.5% | 0.6% |
| Operating margin | −46.8% | −90.5% | −88.7% | −82.2% | −62.1% |
| Net income | −$124M | −$165M | −$143M | −$76.4M | −$196M |
| Net margin | −59.1% | −105.2% | −98.0% | −52.6% | −134.2% |
| Diluted EPS | −$1.65 | −$2.02 | −$18.79 | −$14.00 | −$17.93 |
| Cash | |||||
| Cash from operations | −$107M | −$150M | −$92.7M | −$127M | −$75.4M |
| Capital expenditure | $0.2M | $0.1M | $0.0M | $0.1M | $0.0M |
| Free cash flow | −$107M | −$150M | −$92.7M | −$128M | −$75.4M |
| FCF margin | −51.2% | −95.3% | −63.5% | −87.9% | −51.6% |
| Share count change | 4.4% | −99.9% | −90.7% | 11.8% | 28.2% |
| Debt and strength | |||||
| Cash and short-term investments | $229M | $278M | $191M | $109M | $63.7M |
| Debt incl. finance leases | $169M | — | — | — | — |
| Shareholders' equity | −$79.7M | −$16.7M | −$136M | −$186M | −$293M |
| Current ratio | 3.7x | 5.3x | 3.4x | 1.7x | 1.1x |
| Interest coverage | −3.8x | −5.7x | −5.4x | −3.2x | −2.0x |
| Returns and quality | |||||
| Piotroski F-score | 3 | 3 | 3 | 2 | 2 |
| Altman Z'' | −10.6 | −9.7 | −19.7 | −33.9 | −58.6 |
Insiders bought, 12 months
$0.0M
0 insiders
Insiders sold, 12 months
$0.4M
7 insiders
Of sales under plans
0%
$0.0M
How to read these numbers
- Revenue:
- Total sales reported in the income statement.
- Operating margin:
- Operating income as a share of revenue.
- Net income:
- Profit after all expenses, interest and tax.
- Free cash flow:
- Cash from operations minus capital spending.
- Net debt / EBITDA:
- Years of EBITDA needed to pay off net debt. Below zero means more cash than debt.
- Return on capital:
- After-tax operating income as a share of the money invested in the business: debt plus equity, minus cash.
Karyopharm Therapeutics Inc. · KPTI
Charts and comparison
Ten years at a glance, and how it stacks up against similar companies.
Revenue
Net income
Margins, % of revenue
Cash vs debt (incl. leases)
Free cash flow
Dividends and buybacks
KIRA
At $0.52 a share, the company is worth $0.0M.
Source: SEC EDGAR XBRL filings (CIK 0001503802). Data updated October 24, 2026. For information only — not investment advice. Check the original filings before relying on any figure.